Ifp Advisors, Inc Karuna Therapeutics, Inc. Transaction History

Ifp Advisors, Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Jul 30, 2024	SELL	$0.0 - $329.83 $0 - $989	-3 Reduced 0.37%	817 $0
Q4 2023 Jan 09, 2024	SELL	$161.01 - $317.85 $1,610 - $3,178	-10 Reduced 1.2%	820 $259,000
Q3 2023 Oct 12, 2023	BUY	$164.66 - $218.08 $2,634 - $3,489	16 Added 1.97%	830 $140,000
Q2 2023 Aug 04, 2023	SELL	$176.32 - $240.22 $2,292 - $3,122	-13 Reduced 1.57%	814 $176,000
Q1 2023 Apr 18, 2023	BUY	$161.33 - $204.36 $47,592 - $60,286	295 Added 55.45%	827 $150,000
Q4 2022 Feb 07, 2023	BUY	$191.53 - $236.82 $30,261 - $37,417	158 Added 42.25%	532 $36,000
Q3 2022 Nov 08, 2022	BUY	$123.79 - $277.42 $46,297 - $103,755	374 New	374 $35,000
Q3 2021 Oct 06, 2021	SELL	$101.2 - $125.87 $0 - $0	0 Closed	0 $0
Q2 2021 Jul 13, 2021	SELL	$107.45 - $135.95 $111,640 - $141,252	-1,039 Closed	0 $0
Q1 2021 Apr 30, 2021	BUY	$95.46 - $133.08 $9,450 - $13,174	99 Added 10.53%	1,039 $127,000
Q4 2020 Jan 25, 2021	BUY	$75.23 - $109.23 $1,053 - $1,529	14 Added 1.51%	940 $96,000
Q3 2020 Oct 29, 2020	BUY	$71.31 - $109.74 $66,033 - $101,619	926 New	926 $70,000

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.